Condition (MeSH)
Granuloma Annulare
ClinicalTrials.gov lists 10 trials for Granuloma Annulare or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
10 of the 10 trials are tagged with Granuloma Annulare itself; the rest are tagged with a narrower condition beneath it.
When did Granuloma Annulare trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 4
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 1 |
| 2022 | 2 |
| 2019 | 1 |
| 2018 | 1 |
| 2008 | 1 |
| 2002 | 1 |
| 1997 | 1 |
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 10 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Granuloma Annulare trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2 | 2 |
| Phase 4 | 1 |
| Not applicable | 1 |
| Observational | 3 |
How many Granuloma Annulare trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 8 |
| Terminated | 1 |
| Withdrawn | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Granuloma Annulare trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| AI Labs Group S.L | 1 |
| Istanbul Training and Research Hospital | 1 |
| TWi Biotechnology, Inc. | 1 |
Which drugs are being tested for Granuloma Annulare? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Abrocitinib | 1 |
| (CP-6890,550) Tofacitinib | 1 |
Interventions as named in the registry (3)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| AC-1101 | 1 |
| Corticosteroid with lidocaine | 1 |
| Deucravacitinb | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Granuloma Annulare? (4)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Pentoxifylline in dermatology. | Journal of cosmetic dermatology | 2023 | Yes |
| Treatment of granuloma annulare and suppression of proinflammatory cytokine activity with tofacitinib. | The Journal of allergy and clinical immunology | 2021 | Yes |
| Dimethyl fumarate - only an anti-psoriatic medication? | Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG | 2012 | Yes |
| Generalized granuloma annulare--response to doxycycline. | Journal of the European Academy of Dermatology and Venereology : JEADV | 2009 | Yes |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.